| Steven J Bohinc, MD | |
|
10500 Montgomery Rd, Cincinnati, OH 45242 | |
| (513) 865-2246 | |
| (513) 865-5596 |
| Full Name | Steven J Bohinc |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 11 Years |
| Location | 10500 Montgomery Rd, Cincinnati, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518301654 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 35.130933 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Good Samaritan Hospital | Cincinnati, OH | Hospital |
| Mccullough-hyde Memorial Hospital | Oxford, OH | Hospital |
| Bethesda North | Cincinnati, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Trihealth H Llc | 1850570458 | 668 |
News Archive
A team of researchers from the UK and Finland has discovered why people who stay in education longer have a lower risk of developing dementia - a question that has puzzled scientists for the past decade.
Dartmouth and Dartmouth-Hitchcock Norris Cotton Cancer Center will serve as one of the lead institutions for a new multi-center clinical trial of anti-VISTA, now open and recruiting for patient enrollment.
Oral Squamous Cell Carcinoma (OSCC) is responsible for nearly a quarter of all head and neck cancers. It is one of the leading causes of cancer death - largely due to the failure of current histological procedures in predicting the recurrence of the disease. New research published in BioMed Central's open access journal BMC Cancer shows that a four-gene signature may accurately predict which patients are at higher risk of OSCC recurrence.
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 2a clinical trial that will evaluate multiple combinations of VX-770 and VX-809, investigational oral cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis (CF). The trial is designed to evaluate the safety and tolerability of VX-809 dosed alone for 14 days followed by dosing of VX-809 in combination with VX-770 for 7 days.
The Paul G. Allen Family Foundation announced today the award of Allen Distinguished Investigator (ADI) grants to five teams of researchers with projects that will open new and innovative avenues of research in Alzheimer's disease by uncovering its elusive biological roots.
› Verified 3 days ago
| Entity Name | Trihealth G Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295862944 PECOS PAC ID: 0749222651 Enrollment ID: O20050601000358 |
News Archive
A team of researchers from the UK and Finland has discovered why people who stay in education longer have a lower risk of developing dementia - a question that has puzzled scientists for the past decade.
Dartmouth and Dartmouth-Hitchcock Norris Cotton Cancer Center will serve as one of the lead institutions for a new multi-center clinical trial of anti-VISTA, now open and recruiting for patient enrollment.
Oral Squamous Cell Carcinoma (OSCC) is responsible for nearly a quarter of all head and neck cancers. It is one of the leading causes of cancer death - largely due to the failure of current histological procedures in predicting the recurrence of the disease. New research published in BioMed Central's open access journal BMC Cancer shows that a four-gene signature may accurately predict which patients are at higher risk of OSCC recurrence.
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 2a clinical trial that will evaluate multiple combinations of VX-770 and VX-809, investigational oral cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis (CF). The trial is designed to evaluate the safety and tolerability of VX-809 dosed alone for 14 days followed by dosing of VX-809 in combination with VX-770 for 7 days.
The Paul G. Allen Family Foundation announced today the award of Allen Distinguished Investigator (ADI) grants to five teams of researchers with projects that will open new and innovative avenues of research in Alzheimer's disease by uncovering its elusive biological roots.
› Verified 3 days ago
| Entity Name | Trihealth H Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811215742 PECOS PAC ID: 1850570458 Enrollment ID: O20110128000356 |
News Archive
A team of researchers from the UK and Finland has discovered why people who stay in education longer have a lower risk of developing dementia - a question that has puzzled scientists for the past decade.
Dartmouth and Dartmouth-Hitchcock Norris Cotton Cancer Center will serve as one of the lead institutions for a new multi-center clinical trial of anti-VISTA, now open and recruiting for patient enrollment.
Oral Squamous Cell Carcinoma (OSCC) is responsible for nearly a quarter of all head and neck cancers. It is one of the leading causes of cancer death - largely due to the failure of current histological procedures in predicting the recurrence of the disease. New research published in BioMed Central's open access journal BMC Cancer shows that a four-gene signature may accurately predict which patients are at higher risk of OSCC recurrence.
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 2a clinical trial that will evaluate multiple combinations of VX-770 and VX-809, investigational oral cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis (CF). The trial is designed to evaluate the safety and tolerability of VX-809 dosed alone for 14 days followed by dosing of VX-809 in combination with VX-770 for 7 days.
The Paul G. Allen Family Foundation announced today the award of Allen Distinguished Investigator (ADI) grants to five teams of researchers with projects that will open new and innovative avenues of research in Alzheimer's disease by uncovering its elusive biological roots.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Steven J Bohinc, MD 4685 Forest Ave, Cincinnati, OH 45212-3397 Ph: (513) 853-4722 | Steven J Bohinc, MD 10500 Montgomery Rd, Cincinnati, OH 45242 Ph: (513) 865-2246 |
News Archive
A team of researchers from the UK and Finland has discovered why people who stay in education longer have a lower risk of developing dementia - a question that has puzzled scientists for the past decade.
Dartmouth and Dartmouth-Hitchcock Norris Cotton Cancer Center will serve as one of the lead institutions for a new multi-center clinical trial of anti-VISTA, now open and recruiting for patient enrollment.
Oral Squamous Cell Carcinoma (OSCC) is responsible for nearly a quarter of all head and neck cancers. It is one of the leading causes of cancer death - largely due to the failure of current histological procedures in predicting the recurrence of the disease. New research published in BioMed Central's open access journal BMC Cancer shows that a four-gene signature may accurately predict which patients are at higher risk of OSCC recurrence.
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 2a clinical trial that will evaluate multiple combinations of VX-770 and VX-809, investigational oral cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis (CF). The trial is designed to evaluate the safety and tolerability of VX-809 dosed alone for 14 days followed by dosing of VX-809 in combination with VX-770 for 7 days.
The Paul G. Allen Family Foundation announced today the award of Allen Distinguished Investigator (ADI) grants to five teams of researchers with projects that will open new and innovative avenues of research in Alzheimer's disease by uncovering its elusive biological roots.
› Verified 3 days ago
Smith Bearelly, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 10500 Montgomery Rd, Cincinnati, OH 45242 Phone: 513-865-2246 Fax: 513-865-5596 | |
Dr. Caitlin Ann Richter, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 234 Goodman St, Ml0781, Cincinnati, OH 45219 Phone: 513-584-4505 Fax: 513-584-0468 | |
Muhammad Yaseen, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 375 Dixmyth Ave, Cincinnati, OH 45220 Phone: 513-862-3306 Fax: 513-862-3421 | |
Sandra E Dickens, MD Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 375 Dixmyth Ave, Cincinnati, OH 45220 Phone: 513-872-3452 Fax: 513-872-3421 | |
Juan Carlos Mejia, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 375 Dixmyth Ave, Cincinnati, OH 45220 Phone: 513-862-3452 Fax: 513-862-3421 | |
Amanda Schondelmeyer, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 3333 Burnet Ave, Ml 3016, Cincinnati, OH 45229 Phone: 513-636-4588 Fax: 513-636-0345 | |
Dr. Juan Fernando Martinez, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 234 Goodman St, Cincinnati, OH 45219 Phone: 513-475-8000 |